Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
Indianapolis, IN
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Indianapolis, IN
- Modalities
- mRNA/LNP, Lipid Nanoparticle Formulation, Sterile Injectable Fill-Finish, siRNA/LNP, saRNA/LNP, pDNA/LNP, Oligonucleotide/LNP, Liposomal Complexes
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA/LNP, Lipid Nanoparticle Formulation, Sterile Injectable Fill-Finish, siRNA/LNP, saRNA/LNP, pDNA/LNP, Oligonucleotide/LNP, Liposomal Complexes
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (8 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Broad modality coverage (8 modalities)
Frequently Asked Questions About Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)
What is Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site)'s CDMO Signal Score?
Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site) has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site) for a manufacturing program?
Use the free AI matchmaker to compare Exelead (now MilliporeSigma / Merck KGaA — Indianapolis LNP Site) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: